Loxo Oncology (LOXO) Reports Q3 Loss of $2.26/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Loxo Oncology (LOXO) PT Lowered to $185 at Oppenheimer
November 8, 2018 10:51 AM ESTOppenheimer analyst Leah Rush Cann lowered the price target on Loxo Oncology (NASDAQ: LOXO) to $185.00 (from $202.00) while maintaining a Outperform rating.
Cann commented, "Loxo's lower than estimated 3Q18 loss resulted from net collaboration revenue recognition of $42.5 million. This, in turn, arose from $52.9 million in... More
